Outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100% Meeting Abstract
| Authors: | Jomenez Alguilar, E.; Gainor, J.; Kravets, S.; Khosrowjerdi, S.; Lydon, C.; Adeni, A.; Subegdjo, S.; Rizvi, H.; Hellmann, M.; Awad, M. |
| Abstract Title: | Outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100% |
| Meeting Title: | IASLC 19th World Conference on Lung Cancer |
| Keywords: | immunotherapy; pd-l1; pembrolizumab |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 13 |
| Issue: | 10 Suppl. |
| Meeting Dates: | 2018 Sep 23-26 |
| Meeting Location: | Toronto, Canada |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-10-01 |
| Start Page: | S367 |
| End Page: | S368 |
| Language: | English |
| ACCESSION: | WOS:000454014500324 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2018.08.343 |
| Notes: | Meeting Abstract: MA04.05 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work